Nano Today, volume 48, pages 101692

Engineering nanoparticle communication in living systems by stigmergy: An application to enhance antitumor therapy in triple-negative breast cancer

Alejandra Estepa-Fernández 1, 2, 3
Alba García Fernández 1, 2, 3
Araceli Lérida-Viso 1, 2, 3, 4
Ángela Morellá-Aucejo 1, 2, 3
Juan José Esteve-Moreno 1, 2, 3
Juan F Blandez 1, 2, 3, 4
María Alfonso 2
Vicente Candela-Noguera 2, 3
Gema Vivo-Llorca 2, 3
Félix Sancenon-Galarza 1, 2, 3, 4
Mar Orzáez 3, 5
Show full list: 12 authors
Publication typeJournal Article
Publication date2023-02-01
Journal: Nano Today
scimago Q1
wos Q1
SJR3.483
CiteScore21.5
Impact factor13.2
ISSN17480132, 1878044X
Pharmaceutical Science
Biotechnology
General Materials Science
Bioengineering
Biomedical Engineering
Abstract
The engineering of nanoparticle communication has gained growing attention in the last years, however, efforts to communicate nanoparticles with living systems is still a barely studied emerging topic. Here, we explore a nanoparticle cooperation strategy that involves nanoparticle-cell-nanoparticle communication in vivo through stigmergy (a strategy in which nanodevices communicate by modifying the environment). First, mesoporous silica nanoparticles loaded with the senescence inductor palbociclib and coated with a heterobifunctional poly(ethylene glycol) that binds covalently to a MUC1-binding aptamer (NP(palbo)PEG-MUC1), is designed to specifically deliver the pro-senescent drug palbociclib in MDA-MB-231 breast cancer cells. Once the first nanoparticle modifies the environment due to the induction of senescence, a second community of nanoparticles, loaded with the senolytic navitoclax and coated with a hexa-oligo-saccharide (NP(nav)-Gal), releases its cargo to eliminate tumor senescent cells selectively. The targeted therapy through stigmergy communication is tested in vitro, and in vivo, where delays tumor growth and reduces metastases in a mouse model of human triple-negative breast cancer while minimizing undesired drugs side effects.
Found 
Found 

Top-30

Journals

1
2
1
2

Publishers

1
2
3
4
5
1
2
3
4
5
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Share
Cite this
GOST | RIS | BibTex
Found error?